RNA drug developer Ribo Life targets fresh funding channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
Recent Articles
RELATED ARTICLES
-
As Covid drug cash dwindles, Vigonvita targets new remedies
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Innogen Pharma jostles for a slice of the weight-loss market
